Please assess the completion status of the following clinical trial:

Trial Title: Multi-center Study for Stent Graft System for Peripheral Artery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rutherford 2-5 category~* Subject has read, understood and signed written informed consent which has been reviewed and approved by the Institutional Review Board (IRB).~* At least 20 years of age.~* Ankle-brachial index (ABI) in the study limb in the non-invasive lower extremity arterial studies within 30 days prior to study procedure or at the time of study procedure is less than or equal to 0.9, or toe-brachial index (TBI) is less than or equal to 0.5.~* Male, infertile female, or female of child-bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure.~* Projected life expectancy of greater than 2 years.~* The ability to comply with the study protocol, follow-up requirements and required testing.~* Surgical bypass candidate~* Qualifying lesions by angiography~Exclusion Criteria:~* Untreated flow-limiting aortoiliac disease.~* Any previous stenting or surgery in the target vessel(i.e. femoro-popliteal artery).~* Vascular access/catheterization in the target or contralateral limb within 30 days of study enrollment.~* Planned surgery or intervention within 30 days after study procedure.~* Femoral artery or popliteal artery aneurysm \> 1.5 X healthy adjacent vessel diameter.~* Non-atherosclerotic disease resulting in stenosis and/or occlusion (e.g., embolism, Buerger's disease, vasculitis).~* Severe medical comorbidities (untreated CAD/CHF (Congestive Heart Failure), severe COPD (Chronic Obstructive Pulmonary Disease), severe dementia, NYHA (New York Heart Association) 3/4, severe hypertension, etc.)~* Any medical condition that would preclude post-procedural ambulation or completion of study follow-up.~* Rutherford 5 patients with active infection.~* Serum creatinine \>2.5 mg/dL within 30 days prior to study procedure.~* Rutherford 6 category in the study or non-study limb or major tissue loss extending above the proximal phalanx level.~* Rutherford 5 characteristics in non-study limb.~* Major distal amputation (above the transmetatarsal) in the study or non-study limb.~* Active infection that could adversely impact patient outcomes in the study, or any patient with septicemia or bacteremia.~* Any previously known coagulation disorder, including hypercoagulability.~* Morbid obesity or operative scarring that precludes percutaneous approach~* Contraindication to anticoagulation or antiplatelet~* Known allergies to stent/stent-graft components, including heparin sensitivity, allergy, or previous incidence of heparin-induced thrombocytopenia (HIT) type II.~* Current peritoneal or hemodialysis~* Participation in another clinical trial (except F/P device clinical trial) up to 3 months prior to study enrollment.~* Enrollment in a F/P device clinical trial within the last 12 months.~* Interventional or surgical treatment on arteries distal to the target vessel for this study within the past 12 months.~* Any other factor identified by the Principal Investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GP1101 (Type: EXPERIMENTAL): Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
- Retrospective Surgical Bypass Outcomes (Type: NO_INTERVENTION): Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).